Focused On-demand Library for Phospholipase A2 group XV

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

1-O-acylceramide synthase; LCAT-like lysophospholipase; Lysophospholipase 3; Lysosomal phospholipase A and acyltransferase; Lysosomal phospholipase A2

Alternative UPACC:

Q8NCC3; B3KMF3; B4DUD1; Q53GZ1; Q9NPQ6; Q9UG04; Q9Y2B3


Phospholipase A2 group XV, known by alternative names such as 1-O-acylceramide synthase and Lysosomal phospholipase A2, plays a crucial role in glycerophospholipid homeostasis. It exhibits dual calcium-independent phospholipase and O-acyltransferase activities, essential for remodeling acyl groups of lipophilic alcohols in acidic cellular compartments. This protein is pivotal in the hydrolysis of phospholipids and the transfer of fatty acyl groups to lipophilic alcohols, with a preference for unsaturated fatty acyl groups and natural lipophilic alcohols as acceptors.

Therapeutic significance:

Understanding the role of Phospholipase A2 group XV could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.